Skip to main content

Advertisement

SpringerLink
Log in

Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?

  • Practice Point
  • Published:

From Nature Clinical Practice Nephrology

View current issue Sign up to alerts

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sayegh MH and Turka LA (1998) The role of T-cell costimulatory activation pathways in transplant rejection N Engl J Med 338: 1813–1821

    Article  CAS  Google Scholar 

  2. Larsen CP et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443–453

    Article  CAS  Google Scholar 

  3. Tran HT et al. (2000) Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903–1909

    CAS  PubMed  Google Scholar 

  4. Kreis H et al. (2004) Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809–817

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Warren E Grupe and John P Merrill Chair in Transplantation Medicine and Professor of Medicine and Pediatrics at Harvard Medical School and Director of the Transplantation Research Center in the Renal Division at the Brigham and Women's Hospital and Children's Hospital, Boston, MA, USA

    Mohamed H Sayegh

  2. the Director of the Renal Transplant Clinics at the Brigham and Women's Hospital, Assistant Professor of Medicine at Harvard Medical School and a Principal Investigator at the Transplantation Research Center at the Brigham and Women's Hospital and the Children's Hospital, Boston, MA, USA

    Anil Chandraker

Authors
  1. Mohamed H Sayegh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anil Chandraker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anil Chandraker.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sayegh, M., Chandraker, A. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?. Nat Rev Nephrol 2, 134–135 (2006). https://doi.org/10.1038/ncpneph0125

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0125

  • Springer Nature Limited

Search

Navigation